ArticleAmerican journal of physiology. Lung cellular and molecular physiology2019
Antiviral immunity is impaired in COPD patients with frequent exacerbations.
Article in American journal of physiology. Lung cellular and molecular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 68 citations in OpenAlex.
- Efficacy of Xiyanping in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease and Its Effect on the Expression of GDF-15 and HIF-1Computational and mathematical methods in medicine · 2022Trial
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.The Lancet. Respiratory medicine · 2021Trial
- Review
- Viral dsRNA drives hyperinflammatory but blunted antiviral responses with enhanced PD-L1 induction in a COPD-like airway epithelial model.Biochemistry and biophysics reports · 2026Article
- Review
- A targeted antioxidant nanomedicine regulates mitochondrial ROS and antiviral immunity in rhinovirus-infected human bronchial epithelial cells.Drug delivery and translational research · 2026Article
- Joint clinical and molecular subtyping of COPD with variational autoencoders.Nature communications · 2026Article
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Associations of serum and bronchoalveolar immunoglobulins with lung microbiota diversity, B-cell memory phenotypes, and COPD morbidity and exacerbations.Respiratory research · 2025Observational
- Inhibition of IL-4Rα reduces CCL26 in bronchial epithelial cells from COPD patients.ERJ open research · 2025Article
- Interplay between Lung Diseases and Viral Infections: A Comprehensive Review.Microorganisms · 2024Review
- Sex and disease regulate major histocompatibility complex class I expression in human lung epithelial cells.Physiological reports · 2024Article
- Expression of human Interferon Regulatory Factor 3 (IRF-3) in alveolar macrophages relates to clinical and functional traits in COPD.Respiratory research · 2024Article
- Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype.Molecular medicine reports · 2024Article
- Neutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations.Nature communications · 2024Article
- ARL5b inhibits human rhinovirus 16 propagation and impairs macrophage-mediated bacterial clearance.EMBO reports · 2024Article
- Interferon lambda in respiratory viral infection: immunomodulatory functions and antiviral effects in epithelium.Frontiers in immunology · 2024Review
- The airway mycobiome and interactions with immunity in health and chronic lung disease.Oxford open immunology · 2024Review
- How inhaled corticosteroids target inflammation in COPD.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Obesity dysregulates the pulmonary antiviral immune response.Nature communications · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
Abstract
Patients with frequent exacerbations represent a chronic obstructive pulmonary disease (COPD) subgroup requiring better treatment options. The aim of this study was to determine the innate immune mechanisms that underlie susceptibility to frequent exacerbations in COPD. We measured sputum expression of immune mediators and bacterial loads in samples from patients with COPD at stable state and during virus-associated exacerbations. In vitro immune responses to rhinovirus infection in differentiated primary bronchial epithelial cells (BECs) sampled from patients with COPD were additionally evaluated. Patients were stratified as frequent exacerbators (≥2 exacerbations in the preceding year) or infrequent exacerbators (<2 exacerbations in the preceding year) with comparisons made between these groups. Frequent exacerbators had reduced sputum cell mRNA expression of the antiviral immune mediators type I and III interferons and reduced interferon-stimulated gene (ISG) expression when clinically stable and during virus-associated exacerbation. A role for epithelial cell-intrinsic innate immune dysregulation was identified: induction of interferons and ISGs during in vitro rhinovirus (RV) infection was also impaired in differentiated BECs from frequent exacerbators. Frequent exacerbators additionally had increased sputum bacterial loads at 2 wk following virus-associated exacerbation onset. These data implicate deficient airway innate immunity involving epithelial cells in the increased propensity to exacerbations observed in some patients with COPD. Therapeutic approaches to boost innate antimicrobial immunity in the lung could be a viable strategy for prevention and treatment of frequent exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.